TMO

Thermo Fisher Scientific Inc

TMO, USA

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

https://www.thermofisher.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.43

Next Payout:

Jan 15, 2026

Yield:

0.2780 %
TMO
stock
TMO

P/E Ratio Insights for Thermo Fisher Scientific Benzinga

Read more →
TMO
stock
TMO

Thermo Fisher (TMO) stock rises as Goldman lifts target ahead of Jan. 29 earnings TechStock²

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$641.5653

Analyst Picks

Strong Buy

18

Buy

7

Hold

6

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

35.84

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

4.58

Low 1

High 3

Return on Equity (ROE)

-

Very Low

3.17 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.57 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

16.50 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.02

Low 1

High 0.3

Investors

* Institutions hold a combined 62.09% of the total shares of Thermo Fisher Scientific Inc

1.

Vanguard Group Inc

(8.9481%)

since

2025/06/30

2.

BlackRock Inc

(7.2376%)

since

2025/06/30

3.

State Street Corp

(4.3645%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(3.4103%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.1408%)

since

2025/07/31

6.

Capital World Investors

(2.5366%)

since

2025/06/30

7.

Vanguard 500 Index Investor

(2.4746%)

since

2025/07/31

8.

JPMorgan Chase & Co

(2.4242%)

since

2025/06/30

9.

Geode Capital Management, LLC

(2.149%)

since

2025/06/30

10.

NORGES BANK

(1.4791%)

since

2025/06/30

11.

T. Rowe Price Associates, Inc.

(1.4721%)

since

2025/06/30

12.

Capital Research Global Investors

(1.439%)

since

2025/06/30

13.

Franklin Resources Inc

(1.297%)

since

2025/06/30

14.

Fidelity 500 Index

(1.2672%)

since

2025/07/31

15.

SPDR® S&P 500® ETF

(1.208%)

since

2025/08/31

16.

iShares Core S&P 500 ETF

(1.203%)

since

2025/08/31

17.

FMR Inc

(1.0569%)

since

2025/06/30

18.

Bank of America Corp

(1.0395%)

since

2025/06/30

19.

Northern Trust Corp

(0.955%)

since

2025/06/30

20.

Vanguard Value Index Inv

(0.886%)

since

2025/07/31

21.

Royal Bank of Canada

(0.8782%)

since

2025/06/30

22.

UBS Asset Mgmt Americas Inc

(0.8138%)

since

2025/06/30

23.

Charles Schwab Investment Management Inc

(0.7946%)

since

2025/06/30

24.

Pictet Asset Manangement SA

(0.7543%)

since

2025/06/30

25.

Flossbach von Storch AG

(0.7222%)

since

2025/06/30

26.

Fisher Asset Management, LLC

(0.7123%)

since

2025/06/30

27.

The Health Care Select Sector SPDR® ETF

(0.6826%)

since

2025/08/31

28.

Capital Group Growth Fnd of Amer Comp

(0.6743%)

since

2025/06/30

29.

American Funds Growth Fund of Amer A

(0.6743%)

since

2025/06/30

30.

Vanguard Institutional Index I

(0.6044%)

since

2025/07/31

31.

American Funds New Perspective A

(0.548%)

since

2025/06/30

32.

Capital Group New Perspective Comp

(0.548%)

since

2025/06/30

33.

State St S&P 500® Indx SL Cl III

(0.5336%)

since

2025/08/31

35.

American Funds Invmt Co of Amer A

(0.5%)

since

2025/06/30

36.

Capital Group Fundamental Invtrs Comp

(0.4543%)

since

2025/06/30

37.

American Funds Fundamental Invs A

(0.4543%)

since

2025/06/30

38.

Putnam US Large Cap Value Equity

(0.4219%)

since

2025/06/30

39.

Putnam Large Cap Value A

(0.4219%)

since

2025/07/31

40.

Parnassus Core Equity Investor

(0.4108%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

6.45

Latest Release

Date

2025-09-30

EPS Actual

5.79

EPS Estimate

5.5

EPS Difference

0.29

Surprise Percent

5.2727%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(9)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(7.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(6.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.